First Header Logo Second Header Logo

Connection

Michelle Mielke to Positron-Emission Tomography

This is a "connection" page, showing publications Michelle Mielke has written about Positron-Emission Tomography.
Connection Strength

0.881
  1. Singh NA, Alnobani A, Graff-Radford J, Machulda MM, Mielke MM, Schwarz CG, Senjem ML, Jack CR, Lowe VJ, Kanekiyo T, Josephs KA, Whitwell JL. Relationships between PET and blood plasma biomarkers in corticobasal syndrome. Alzheimers Dement. 2024 Jul; 20(7):4765-4774.
    View in: PubMed
    Score: 0.220
  2. Sintini I, Singh NA, Li D, Mielke MM, Machulda MM, Schwarz CG, Senjem ML, Jack CR, Lowe VJ, Graff-Radford J, Josephs KA, Whitwell JL. Plasma glial fibrillary acidic protein in the visual and language variants of Alzheimer's disease. Alzheimers Dement. 2024 May; 20(5):3679-3686.
    View in: PubMed
    Score: 0.216
  3. Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, Bu G, Vemuri P, Graff-Radford J, Jack CR, Petersen RC. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022 Jul; 28(7):1398-1405.
    View in: PubMed
    Score: 0.190
  4. Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Suárez-Calvet M, Khachaturian AS, Mielke MM, Udeh-Momoh C, Weiss J, Batrla R, Bozeat S, Dwyer JR, Holzapfel D, Jones DR, Murray JF, Partrick KA, Scholler E, Vradenburg G, Young D, Algeciras-Schimnich A, Aubrecht J, Braunstein JB, Hendrix J, Hu YH, Mattke S, Monane M, Reilly D, Somers E, Teunissen CE, Shobin E, Vanderstichele H, Weiner MW, Wilson D, Hansson O. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease. Nat Rev Neurol. 2024 Jul; 20(7):426-439.
    View in: PubMed
    Score: 0.055
  5. Jack CR, Wiste HJ, Algeciras-Schimnich A, Weigand SD, Figdore DJ, Lowe VJ, Vemuri P, Graff-Radford J, Ramanan VK, Knopman DS, Mielke MM, Machulda MM, Fields J, Schwarz CG, Cogswell PM, Senjem ML, Therneau TM, Petersen RC. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals. Alzheimers Dement. 2024 Mar; 20(3):2143-2154.
    View in: PubMed
    Score: 0.053
  6. Cogswell PM, Lundt ES, Therneau TM, Wiste HJ, Graff-Radford J, Algeciras-Schimnich A, Lowe VJ, Mielke MM, Schwarz CG, Senjem ML, Gunter JL, Knopman DS, Vemuri P, Petersen RC, Jack CR. Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET. Alzheimers Dement. 2024 Feb; 20(2):1225-1238.
    View in: PubMed
    Score: 0.053
  7. Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, Salloway S, Sperling R, Zetterberg H, Teunissen CE. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022 Dec; 18(12):2669-2686.
    View in: PubMed
    Score: 0.048
  8. Vassilaki M, Crowson CS, Davis Iii JM, Duong SQ, Jones DT, Nguyen A, Mielke MM, Vemuri P, Myasoedova E. Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging. J Alzheimers Dis. 2022; 89(3):943-954.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.